• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silence Therapeutics Plc - American Depository Share (NQ:SLN)

    5.540 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 5.540
    Bid (Size) 5.450 (9)
    Ask (Size) 5.950 (3)
    Prev. Close 5.540
    Today's Range 5.540 - 5.540
    52wk Range 1.970 - 20.48
    Shares Outstanding 107,808,471
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Silence Therapeutics to Participate in September Investor Conferences
    From Silence Therapeutics plc
    Via Business Wire
    Silence (SLN) Q2 Revenue Drops 71%
    Via The Motley Fool

    Performance

    YTD
    -22.9%
    -22.9%
    1 Month
    +15.2%
    +15.2%
    3 Month
    -4.5%
    -4.5%
    6 Month
    +96.5%
    +96.5%
    1 Year
    -69.5%
    -69.5%

    More News

    Read More
    Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
    From Silence Therapeutics plc
    Via Business Wire
    Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
    Via Benzinga
    Earnings Scheduled For February 27, 2025
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Welcomes Tim McInerney to Board of Directors
    From Silence Therapeutics plc
    Via Business Wire
    Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
    Via Benzinga
    The Analyst Landscape: 6 Takes On Silence Therapeutics
    Via Benzinga
    These stocks are moving in today's pre-market session
    Via Chartmill
    Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
    From Silence Therapeutics plc
    Via Business Wire
    Analyst Scoreboard: 4 Ratings For Silence Therapeutics
    Via Benzinga
    Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
    Via Talk Markets
    Topics Stocks / Equities
    Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
    From Silence Therapeutics plc
    Via Business Wire
    This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
    Via Benzinga
    Top 3 Health Care Stocks That May Explode In Q4
    Via Benzinga
    Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
    Via Benzinga
    Top 3 Health Care Stocks You'll Regret Missing In Q4
    Via Benzinga
    Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
    From Silence Therapeutics plc
    Via Business Wire

    Frequently Asked Questions

    Is Silence Therapeutics Plc - American Depository Share publicly traded?
    Yes, Silence Therapeutics Plc - American Depository Share is publicly traded.
    What exchange does Silence Therapeutics Plc - American Depository Share trade on?
    Silence Therapeutics Plc - American Depository Share trades on the Nasdaq Stock Market
    What is the ticker symbol for Silence Therapeutics Plc - American Depository Share?
    The ticker symbol for Silence Therapeutics Plc - American Depository Share is SLN on the Nasdaq Stock Market
    What is the current price of Silence Therapeutics Plc - American Depository Share?
    The current price of Silence Therapeutics Plc - American Depository Share is 5.540
    When was Silence Therapeutics Plc - American Depository Share last traded?
    The last trade of Silence Therapeutics Plc - American Depository Share was at 09/26/25 04:00 PM ET
    What is the market capitalization of Silence Therapeutics Plc - American Depository Share?
    The market capitalization of Silence Therapeutics Plc - American Depository Share is 597.26M
    How many shares of Silence Therapeutics Plc - American Depository Share are outstanding?
    Silence Therapeutics Plc - American Depository Share has 597M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.